Triamcinolone Clinical Trials

Size	Price	Qty
50mg	USD 147

Clinical Trials

Multiple clinical trials evaluate the therapeutic application of triamcinolone in dermatological conditions, specifically focusing on recalcitrant alopecia areata and acne vulgaris under an unassigned phase status. Supported by academic institutions like Al-Azhar University and private entities such as ACOM Labs, these research initiatives encompass a range of recruitment statuses. The studies span completed evaluations of intralesional triamcinolone injections to upcoming protocols investigating combination microneedling procedures.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06088147	Not yet recruiting	Alopecia Areata	Al-Azhar University	2023-12	Not Applicable
NCT06170593	Completed	Acne Vulgaris	ACOM Labs	2022-11-15	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Triamcinolone product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a corticosteroid agonist, triamcinolone binds intracellular glucocorticoid receptors to induce lipocortin synthesis, which inhibits phospholipase A2 and blocks arachidonic acid liberation, thereby preventing downstream prostaglandin and leukotriene cascade activation. The resulting reduction in inflammatory mediator production and immune cell reactivity decreases localized cutaneous inflammation, providing clinical utility in managing dermatological diseases such as alopecia areata and acne vulgaris.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).